Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-Mesothelin CAR-T in Advanced Solid Tumors
NCT07010523Phase 1Recruiting
- Sponsor
- Zhejiang University
- Start
- Oct 2024
- Primary completion
- Oct 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anti-mesothelin CAR vector-transduced autologous T lymphocytes in mesothelioma, pancreatic cancer (PC), biliary tract cancer (BTC) and 8 more, sponsored by Zhejiang University. Primary endpoints: Adverse Events (AEs) at 2 years, Serious Adverse Events (SAEs) at 2 years and 3 more. Started Oct 2024; status: recruiting.
02
Drugs
anti-mesothelin CAR vector-transduced autologous T lymphocytes
03
Conditions
mesotheliomapancreatic cancer (PC)biliary tract cancer (BTC)lung cancerovarian cancer
Beyond the preview
Go deeper on NCT07010523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07010523.